M. Boyce

发表

Effect of IVL745, a VLA-4 antagonist, on allergen-induced bronchoconstriction in patients with asthma.

S. Holgate, B. O'connor, H. Arshad, 2005, The Journal of allergy and clinical immunology.

Crossover study of the haematological effects and pharmacokinetics of glycosylated and non‐glycosylated G‐CSF in healthy volunteers

D. Linch, S. Hartley, S. Warrington, 1997, British journal of haematology.

Phase I Study on Safety and Pharmacokinetics of a Novel Influenza Endonuclease Inhibitor, AL-794 (JNJ-64155806), following Single- and Multiple-Ascending doses in Healthy Adults

P. V. Remoortere, J. Symons, T. Kakuda, 2018, Antiviral therapy.

Pharmacokinetics and Disposition

Boyce, Seymour, S. Lociuro, 2007 .

The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development

I. Drozdov, R. Camp, J. Black, 2010, Regulatory Peptides.

Pharmacokinetics, safety and tolerability of three dosage regimens of buccal adhesive testosterone tablets in healthy men suppressed with leuprorelin.

K. Baisley, S. Bukofzer, S. Warrington, 2002, The Journal of endocrinology.

Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.

J. Reseland, B. Skallerud, A. K. Stunes, 2016, The Journal of endocrinology.

Pharmacokinetics, safety, tolerability and immunogenicity of FKB327, a new biosimilar medicine of adalimumab/Humira, in healthy subjects

A. Niewiarowski, Yasumasa Arai, S. Warrington, 2017, British journal of clinical pharmacology.

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Properties of Taranabant, a Novel Selective Cannabinoid‐1 Receptor Inverse Agonist, for the Treatment of Obesity: Results From a Double‐Blind, Placebo‐Controlled, Single Oral Dose Study in Healthy Volunteers

P. Rothenberg, J. Wagner, K. Gottesdiener, 2008, Journal of clinical pharmacology.

Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose‐dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects

A. Johnston, S. Warrington, M. Boyce, 2012, Alimentary pharmacology & therapeutics.

Randomized study of the safety and pharmacodynamics of inhaled interleukin-13 monoclonal antibody fragment VR942

A. Scrimgeour, G. Burgess, P. Vajjah, 2018, EBioMedicine.

The 5‐lipoxygenase‐activating protein inhibitor, GSK2190915, attenuates the early and late responses to inhaled allergen in mild asthma

B. O'connor, Z. Diamant, V. Norris, 2013, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors

Yongxiang Fang, L. Rainbow, C. Oxvig, 2020, Cellular and molecular gastroenterology and hepatology.

The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression

G. Sanger, P. Hellström, E. Theodorsson, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.

Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial

C. Goldfrad, D. Quinn, M. Boyce, 2012, Clinical and Translational Allergy.

Safety, tolerability, and antiischaemic efficacy of ITF-296, a nitric oxide donor, in patients with chronic stable angina.

R. Senior, R. Khattar, M. Sardina, 1998, Journal of cardiovascular pharmacology.

Potential clinical indications for a CCK2 receptor antagonist.

D. Pritchard, M. Boyce, K. Lloyd, 2016, Current opinion in pharmacology.

Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study

Dave Singh, J. Bentley, V. Norris, 2013, International journal of general medicine.

Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men

K. Cho, S. Warrington, M. Boyce, 2015, Xenobiotica; the fate of foreign compounds in biological systems.

Analysis of 312 studies of investigational medicinal products in healthy subjects to assess the impact of the European Union Clinical Trials Directive

S. Warrington, M. Boyce, 2002, International Journal of Pharmaceutical Medicine.

Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib

G. Dear, A. Kielkowska, A. Cahn, 2019, The Journal of Pharmacology and Experimental Therapeutics.

Genes associated with rheumatoid arthritis and mild inflammatory arthritis. I. Major histocompatibility complex class I, II, and III allotypes.

R. Vaughan, K. Welsh, R. Jacoby, 1990, Annals of the rheumatic diseases.

Inhibition of the histamine wheal by ebastine compared with cetirizine, fexofenadine and loratadine at steady state.

W. Carey, S. Warrington, M. Boyce, 2002, Drugs under experimental and clinical research.

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

B. Bettencourt, Tracy S. Zimmermann, J. Gollob, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

Optimal timing for collection of PBPC after glycosylated G-CSF administration

D. Linch, S. Hartley, S. Warrington, 1998, Bone Marrow Transplantation.

Response: Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity

S. Warrington, M. Boyce, T. Mitchell, 2017, European Journal of Clinical Pharmacology.

Randomised trial of the effect of a gastrin/CCK2 receptor antagonist on esomeprazole-induced hypergastrinaemia: evidence against rebound hyperacidity

S. Warrington, M. Boyce, T. Mitchell, 2016, European Journal of Clinical Pharmacology.

Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.

S. Warrington, M. Boyce, 2013, British journal of clinical pharmacology.

Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.

J. Black, S. Warrington, M. Boyce, 2013, British journal of clinical pharmacology.

Hemodynamic and Electrocardiographic Effects of Almotriptan in Healthy Volunteers

S. Warrington, M. Boyce, K. Dunn, 2001, Journal of cardiovascular pharmacology.

Netazepide, a gastrin/cholecystokinin‐2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis

F. Campbell, D. Pritchard, A. Varró, 2017, British journal of clinical pharmacology.

Single and Repeated Dose First-in-Human Study with the Anti-Hepcidin Spiegelmer Nox-H94.

D. Swinkels, C. Laarakkers, M. Boyce, 2012 .

Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)

B. Miller, R. Mayer, N. Goyal, 2017, British journal of clinical pharmacology.

ONO‐7684 a novel oral FXIa inhibitor: Safety, tolerability, pharmacokinetics and pharmacodynamics in a first‐in‐human study

Paul A. Smith, M. Boyce, Naoki Honda, 2021, British journal of clinical pharmacology.

Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.

J. Black, Chun-Mei Zhao, M. Boyce, 2015, British journal of clinical pharmacology.

FRI0075 SYSTEMATIC ANALYSIS OF INJECTION-SITE PAIN CAUSED BY SUBCUTANEOUS ADMINISTRATION OF THE ADALIMUMAB BIOSIMILAR FKB327 VERSUS ADMINISTRATION OF THE ADALIMUMAB REFERENCE PRODUCT VIA DIFFERENT DELIVERY METHODS

M. Genovese, Takuma Yonemura, H. Kellner, 2019, Poster Presentations.

Clinical effects of human macrophage inflammatory protein-1 alpha MIP-1 alpha (LD78) administration to humans: a phase I study in cancer patients and normal healthy volunteers with the genetically engineered variant, BB-10010.

A. Howell, T. Dexter, L. Czaplewski, 1998, European journal of cancer.

Pharmacokinetics and Tolerability of GW420867X, a Nonnucleoside Reverse Transcriptase Inhibitor, following Single Escalating Doses in Healthy Male Volunteers

W. Prince, A. Jones, T. Hardman, 2001, Journal of clinical pharmacology.

Gastric neuroendocrine tumors: prevalence in Europe, USA, and Japan, and rationale for treatment with a gastrin/CCK2 receptor antagonist

M. Boyce, L. Thomsen, 2015, Scandinavian journal of gastroenterology.

TOPS: an internet-based system to prevent healthy subjects from over-volunteering for clinical trials

J. Kirk, S. Warrington, M. Boyce, 2012, European Journal of Clinical Pharmacology.

Netazepide, a Gastrin Receptor Antagonist, Normalises Tumour Biomarkers and Causes Regression of Type 1 Gastric Neuroendocrine Tumours in a Nonrandomised Trial of Patients with Chronic Atrophic Gastritis

F. Campbell, D. Pritchard, A. Varró, 2013, PloS one.

Effects of rabeprazole, 20 mg, or esomeprazole, 20 mg, on 24‐h intragastric pH and serum gastrin in healthy subjects

K. Baisley, B. Tejura, S. Warrington, 2002, Alimentary pharmacology & therapeutics.

A five way crossover human volunteer study to compare the pharmacokinetics of paracetamol following oral administration of two commercially available paracetamol tablets and three development tablets containing paracetamol in combination with sodium bicarbonate or calcium carbonate.

T. Grattan, S. Warrington, T Grattan, 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

The Gastrin Receptor Antagonist Netazepide (YF476) Prevents Oxyntic Mucosal Inflammation Induced by Helicobacter Pylori Infection in Mongolian Gerbils

G. Qvigstad, I. Nordrum, K. Bergh, 2013, Helicobacter.

Pharmacokinetics, Safety, and Tolerability of Ascending Doses of Sublingual Fentanyl, With and Without Naltrexone, in Japanese Subjects

S. Warrington, M. Boyce, J. Kilborn, 2011, Journal of clinical pharmacology.

The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours: review of long-term treatment

R. Fossmark, P. Mjønes, Liv Sagatun, 2016, European journal of gastroenterology & hepatology.

Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A

G. Qvigstad, R. Fossmark, I. Nordrum, 2012, Alimentary pharmacology & therapeutics.

Pharmacokinetic interaction between domperidone and ketoconazole leads to QT prolongation in healthy volunteers: a randomized, placebo-controlled, double-blind, crossover study.

K. Baisley, S. Warrington, M. Boyce, 2012, British journal of clinical pharmacology.

Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe?

S. Warrington, M. Boyce, G. Peters, 2013, British journal of clinical pharmacology.

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

D. Macmahon, A. Johnston, T. Corn, 2003, Journal of Neural Transmission.

Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn

K. Baisley, S. Warrington, M. Boyce, 2007, Alimentary pharmacology & therapeutics.

Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers.

M. Ravic, A. Johnston, S. Warrington, 2004, British journal of clinical pharmacology.

Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.

J. Kastelein, S. V. van Deventer, S. Warrington, 2014, British journal of clinical pharmacology.

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography

R. Dolan, R. Frackowiak, P. Grasby, 1996, Psychopharmacology.

A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation

J. Black, I. Modlin, M. Culler, 2007, Regulatory Peptides.

Safety, pharmacokinetics and pharmacodynamics of the anti‐hepcidin Spiegelmer lexaptepid pegol in healthy subjects

D. Swinkels, S. Warrington, M. Boyce, 2016, British journal of pharmacology.

Gastrin-induced miR-222 promotes gastric tumor development by suppressing p27kip1

G. Dockray, D. Pritchard, A. Varró, 2016, Oncotarget.

Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration

J. Andreas, K. Yamamoto, M. Boyce, 2015, European Journal of Drug Metabolism and Pharmacokinetics.

A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus

J. Ferbas, M. Horner, N. McHugh, 2013, British journal of clinical pharmacology.

Effects of single doses of rabeprazole 20 mg and esomeprazole 40 mg on 24-h intragastric pH in healthy subjects

K. Baisley, S. Warrington, M. Boyce, 2006, European Journal of Clinical Pharmacology.

Coadministration of Orally Inhaled Zanamivir with Inactivated Trivalent Influenza Vaccine Does Not Adversely Affect the Production of Antihaemagglutinin Antibodies in the Serum of Healthy Volunteers

M. Boyce, A. Webster, S. Edmundson, 1999, Clinical pharmacokinetics.

Immunogenicity of an adalimumab biosimilar, FKB327, and its reference product in patients with rheumatoid arthritis

M. Genovese, K. Kawakami, R. Alten, 2020, International journal of rheumatic diseases.

A microdose study of 14C-AR-709 in healthy men: pharmacokinetics, absolute bioavailability and concentrations in key compartments of the lung

S. Lociuro, T. Matzow, M. Seymour, 2013, European Journal of Clinical Pharmacology.

Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study

D. Nutt, E. Rabiner, A. Lingford-Hughes, 2017, Biological Psychiatry.

Gastrin stimulates a cholecystokinin-2-receptor-expressing cardia progenitor cell and promotes progression of Barrett's-like esophagus

Kenneth K Wang, A. Urbanska, G. Bhagat, 2016, Oncotarget.

Pharmacodynamic Activity of the Novel Neurokinin-3 Receptor Antagonist SJX-653 in Healthy Men

R. Thieroff-Ekerdt, D. Corzo, M. Boyce, 2020, Journal of Clinical Endocrinology and Metabolism.

P422 Immunogenicity of a proposed adalimumab biosimilar, FKB327, and the reference product in patients with rheumatoid arthritis

M. Genovese, K. Kawakami, C. Markland, 2019, Journal of Crohn's and Colitis.

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

H. Fennema, J. Symons, P. van Remoortere, 2018, The Journal of infectious diseases.

Pharmacokinetics of the antiepileptic drug levetiracetam in healthy Japanese and Caucasian volunteers following intravenous administration

J. Andreas, K. Yamamoto, M. Boyce, 2015, European Journal of Drug Metabolism and Pharmacokinetics.

Randomized trial of allergen‐induced asthmatic response in smokers and non‐smokers: effects of inhaled corticosteroids

C. Rambaran, M. Boyce, P. Ventresca, 2015, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

SLN124, a GalNAc conjugated 19‐mer siRNA targeting tmprss6, reduces plasma iron and increases hepcidin levels of healthy volunteers

A. Scrimgeour, M. Aleku, M. Muckenthaler, 2023, American journal of hematology.

Pharmacokinetics of Two 6-Day Frovatriptan Dosing Regimens Used for the Short-Term Prevention of Menstrual Migraine

S. Warrington, M. Boyce, S. Pawsey, 2009, Clinical drug investigation.

Sa2016 Netazepide, a Gastrin/CCK-2 Receptor Antagonist, Causes Regression of Type 1 Gastric Neuroendocrine Tumors and Reduces Expression of Chromogranin a and Histidine Decarboxylase Genes in Chronic Atrophic Gastritis

F. Campbell, D. Pritchard, A. Varró, 2013 .

Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.

B. Bettencourt, Tracy S. Zimmermann, J. Gollob, 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression

G. Sanger, P. Hellström, E. Theodorsson, 2012, Naunyn-Schmiedeberg's Archives of Pharmacology.